Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Verteporfin Clear all
Completed Phase 4 Interventional

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

NCT00680498
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Ranibizumab plus Photodynamic therapy
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

NCT00211458
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

NCT00140803
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2007 · Synced Sep 2, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT06807359
View directory record Official record
Conditions
Prostate Cancer
Interventions
Photodynamic Therapy (PDT), Verteporfin Injection
Device · Drug
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 6:42 PM EDT
Not listed Phase 2 Interventional

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Verteporfin, Continuous Low-Irradiance Photodynamic Therapy (CLIPT)
Drug · Device
Lead sponsor
Rogers Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 2, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

NCT04590664
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Verteporfin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 2, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

NCT03067051
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Verteporfin, SpectraCure P18 System
Drug · Device
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 6:42 PM EDT
Withdrawn Not applicable Interventional

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

NCT02457026
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Aflibercept, Triamcinolone Acetonide, Verteporfin
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Verteporfin, Bevacizumab
Drug
Lead sponsor
Retinal Consultants Medical Group
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00138632
View directory record Official record
Conditions
Wet Age-Related Macular Degeneration
Interventions
PTK787, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00007969
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Detox-B adjuvant, verteporfin
Biological · Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
6
States / cities
Denver, Colorado • Aventura, Florida • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

NCT00211445
View directory record Official record
Conditions
Chronic Central Serous Chorioretinopathy
Interventions
Photodynamic Therapy with Verteporfin, verteporfin
Procedure · Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2007 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

NCT00390208
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, dexamethasone and verteporfin, Ranibizumab
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Sep 2, 2026, 6:42 PM EDT
Withdrawn Phase 1 Interventional

HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

NCT03906643
View directory record Official record
Conditions
Solid Tumor
Interventions
HS-201
Drug
Lead sponsor
Herbert Lyerly
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 2, 2026, 6:42 PM EDT
Withdrawn Phase 4 Interventional

Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

NCT04075136
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

NCT00492284
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
verteporfin, ranibizumab, dexamethasone
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Sep 2, 2026, 6:42 PM EDT
Terminated Not applicable Interventional

Macugen for Histoplasmosis

NCT00272766
View directory record Official record
Conditions
Ocular Histoplasmosis, Choroidal Neovascularization
Interventions
pegaptanib sodium
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 2, 2026, 6:42 PM EDT
Not listed Phase 2 Interventional

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936
View directory record Official record
Conditions
Presumed Ocular Histoplasmosis (POHS)
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 15, 2009 · Synced Sep 2, 2026, 6:42 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

NCT00423189
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab (Lucentis), 0.5mg ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
55 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 2, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional

MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

NCT00094120
View directory record Official record
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Sep 2, 2026, 6:42 PM EDT
Completed No phase listed Observational

Photodynamic Therapy for PDA in NV AMD

NCT02452840
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Macular Degeneration
Interventions
No Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 2, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

NCT03033225
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Neoplasm, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy, Quality-of-Life Assessment, Questionnaire Administration, Verteporfin
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 2, 2026, 6:42 PM EDT